BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Status:
Completed
Trial end date:
2017-03-16
Target enrollment:
Participant gender:
Summary
This randomised, open label phase III trial will be performed in patients with adenocarcinoma
of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation.
The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A,
with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of
patients.